Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

S1P antagonists as adjunct ocular hypotensives

An antagonist and agonist technology, which is applied in the field of S1P antagonists as an auxiliary ocular antihypertensive drug, can solve the problem that the ocular antihypertensive drug combination cannot meet theoretical expectations, the ocular antihypertensive effect cannot be increased, and the ocular antihypertensive Problems such as reduced pressure efficiency

Inactive Publication Date: 2014-02-05
ALLERGAN INC
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, the ocular antihypertensive potency of once-daily bimatoprost (0.03%) could not be increased by higher concentrations or by increased dosing frequency; the ocular antihypertensive potency was actually reduced
In addition, ocular antihypertensive drug combinations often fall short of theoretical expectations

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • S1P antagonists as adjunct ocular hypotensives
  • S1P antagonists as adjunct ocular hypotensives
  • S1P antagonists as adjunct ocular hypotensives

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0010] It should be understood that the foregoing summary and the following detailed description are only exemplary and explanatory, and do not limit the claimed invention. As used herein, unless explicitly stated otherwise, the use of the singular includes the plural. As used herein, "or" means "and / or" unless stated otherwise. In addition, the use of the term "including" and other forms (such as "includes" and "included") are non-limiting. The section headings used in this article are for organizational purposes only and are not construed as limiting the subject described.

[0011] As used herein, a hydrocarbyl group is composed of carbon and hydrogen, where each carbon has 4 covalent bonds and each hydrogen has a single bond to the carbon atom. "Hydrocarbyl fragments" have the same meaning as "hydrocarbyl", but are used only for counting purposes. For example, one or more hydrocarbyl fragments means 1, 2, or more distinct parts each composed of hydrocarbyl groups, and the p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides compositions and methods for further reducing IOP in a subject who has already achieved maximal IOP reduction using known IOP lowering agents. The activity of an ocular hypotensive treatment regimen may be increased by adding an S1P antagonist to prevent S1P mediated reversal as a result of decreased aqueous humor outflow.

Description

[0001] Related application [0002] This application claims the benefit of U.S. Provisional Application Serial No. 61 / 467,690 filed on March 25, 2011, the disclosure of which is hereby incorporated by reference in its entirety. Invention field [0003] The present invention is directed to the combination of SIP antagonists and known IOP lowering drugs for lowering intraocular pressure. Background of the invention [0004] It is well known that efforts to greatly reduce intraocular pressure (IOP) in patients with high intraocular pressure through drug intervention rarely meet expectations. For example, the once-daily bimatoprost (0.03%) ocular antihypertensive efficacy cannot be increased by higher concentration or by increased dosing frequency; the ocular antihypertensive efficacy is actually reduced. In addition, the ocular antihypertensive drug combination usually fails to meet theoretical expectations. There seems to be a "glass floor" that prevents the drug-mediated blood pres...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06
CPCA61K45/06A61K31/5575A61K38/177A61K31/4178A61P25/00A61P25/02A61P27/02A61P43/00A61K9/08A61K31/404A61K31/505A61K31/519
Inventor D·F·伍德沃T·M·海德尔堡W·D·斯塔默
Owner ALLERGAN INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com